Home  |  Contact

UniProtKB/Swiss-Prot P63000: Variant p.Tyr64Asp

Ras-related C3 botulinum toxin substrate 1
Gene: RAC1
Variant information

Variant position:  64
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Tyrosine (Y) to Aspartate (D) at position 64 (Y64D, p.Tyr64Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (Y) to medium size and acidic (D)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Mental retardation, autosomal dominant 48 (MRD48) [MIM:617751]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD48 patients manifest global developmental delay and moderate to severe intellectual disability. {ECO:0000269|PubMed:28886345}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In MRD48; increased substrate adhesion-dependent cell spreading; constitutively active.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  64
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  192
The length of the canonical sequence.

Location on the sequence:   VMVDGKPVNLGLWDTAGQED  Y DRLRPLSYPQTDVFLICFSL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 189 Ras-related C3 botulinum toxin substrate 1
Binding site 60 – 60 GTP; via amide nitrogen
Alternative sequence 75 – 75 T -> TVGETYGKDITSRGKDKPIA. In isoform B.
Mutagenesis 56 – 56 W -> A. Strongly reduced interaction with PLCB2.
Mutagenesis 61 – 61 Q -> L. Constitutively active. Interacts with PARD6 proteins. Interacts with PPP5C, activates its phosphatase activity and translocates PPP5C to the plasma membrane. No effect on interaction with RAPH1. No interaction with PPP5C; when associated with V-30 or S-35. Translocates to the plasma membrane; also when associated with V-30 or S-35.
Mutagenesis 67 – 67 L -> A. Strongly reduced interaction with PLCB2.
Mutagenesis 70 – 70 L -> A. Strongly reduced interaction with PLCB2.
Helix 62 – 64


Literature citations

RAC1 Missense Mutations in Developmental Disorders with Diverse Phenotypes.
Reijnders M.R.F.; Ansor N.M.; Kousi M.; Yue W.W.; Tan P.L.; Clarkson K.; Clayton-Smith J.; Corning K.; Jones J.R.; Lam W.W.K.; Mancini G.M.S.; Marcelis C.; Mohammed S.; Pfundt R.; Roifman M.; Cohn R.; Chitayat D.; Millard T.H.; Katsanis N.; Brunner H.G.; Banka S.;
Am. J. Hum. Genet. 101:466-477(2017)
Cited for: FUNCTION; INVOLVEMENT IN MRD48; VARIANTS MRD48 TYR-18; SER-39; LEU-51; MET-51; ASP-64; LEU-73 AND TYR-157; CHARACTERIZATION OF VARIANTS MRD48 TYR-18; SER-39; MET-51; ASP-64; LEU-73 AND TYR-157;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.